{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epacadostat&page=2",
    "query": {
      "intervention": "Epacadostat",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epacadostat&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T20:02:55.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03322566",
      "title": "A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Platinum-based chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2018-01-09",
      "completion_date": "2020-10-16",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 21,
      "location_summary": "Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03322566"
    },
    {
      "nct_id": "NCT03322384",
      "title": "UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "epacadostat",
          "type": "DRUG"
        },
        {
          "name": "SD-101",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-01-17",
      "completion_date": "2020-04-08",
      "has_results": true,
      "last_update_posted_date": "2022-02-01",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03322384"
    },
    {
      "nct_id": "NCT02559492",
      "title": "Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "INCB050465",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2015-11",
      "completion_date": "2019-08-18",
      "has_results": false,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Denver, Colorado • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02559492"
    },
    {
      "nct_id": "NCT03402880",
      "title": "ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extensive Stage Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-10",
      "completion_date": "2018-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 3,
      "location_summary": "Duarte, California • South Pasadena, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03402880"
    },
    {
      "nct_id": "NCT03291054",
      "title": "Epacadostat and Pembrolizumab in Patients With GIST",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2018-02-28",
      "completion_date": "2020-08-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • New York, New York",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03291054"
    },
    {
      "nct_id": "NCT02042430",
      "title": "Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stage III Fallopian Tube Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Primary Peritoneal Cancer AJCC v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "19 Years and older · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2014-08-25",
      "completion_date": "2016-11-29",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Buffalo, New York",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02042430"
    },
    {
      "nct_id": "NCT03532295",
      "title": "Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2020-04-20",
      "completion_date": "2025-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03532295"
    },
    {
      "nct_id": "NCT03602586",
      "title": "Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Ovarian Clear Cell Tumor",
        "Recurrent Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 14,
      "start_date": "2018-12-21",
      "completion_date": "2024-03-27",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 351,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 209 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602586"
    },
    {
      "nct_id": "NCT02166905",
      "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Carcinoma",
        "Ovarian Carcinoma",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2014-10-10",
      "completion_date": "2020-08-20",
      "has_results": true,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166905"
    },
    {
      "nct_id": "NCT02575807",
      "title": "Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer",
        "Platinum-resistant Fallopian Cancer",
        "Platinum-resistant Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "CRS-207",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Aduro Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2016-03-08",
      "completion_date": "2018-05-08",
      "has_results": true,
      "last_update_posted_date": "2019-04-04",
      "last_synced_at": "2026-09-24T20:02:55.470Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Stanford, California • Gainesville, Florida + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575807"
    }
  ]
}